延髓头端腹外侧区注入肾上腺素对血液流变学的影响

实验用ＳＤ雄性大鼠７８只,采用束缚方法引起应激性高血粘度和血压升高。结果：（１）清醒大鼠束缚２ｄ可引起应激性高血粘度和血压升高。（２）双侧延髓头端腹外侧区（ｒＶＬＭ）微量注射肾上腺素（Ｅ,每侧０．５μｇ／０．５μｌ）可引起血粘度明显增高,此作用可预先在双侧ｒＶＬＭ注入α肾上腺素能受体阻断剂酚妥拉明所阻断,不能被β－肾上腺能受体阻断剂心得安所阻断。用同样剂量Ｅ注入双侧延髓尾端腹外侧区（ｃＶＬＭ）或静     

精氨酸加压素对大鼠抗体产生和淋巴细胞增殖的上调作用

大鼠侧脑室注射１００ｎｇ精氨酸加压素（ＡＶＰ）,用ＥＬＩＳＡ法检测血中对鸡卵白 白抗原产生的ＩｇＧ抗体水平。结果显示,ＩｇＧ水平高于对照,而ＡＶＰ的Ｖ１受体阻断剂ＤＰＡＶＰ则可阻断此作用;ｉｃｖ８００ｎｇＡＶＰ,大鼠的ＳＲＢＣ溶血素 水平高于对照;ｉｃｖ１００ｎｇ、８００ｎｇＡＶＰ２ｈ后,脾淋巴细胞对ＭＴＴ产生的颜色反应均比对照增加,而ＤＰＡＶＰ可阻断之;ｉｃｖ８００ＡＶＰ２ｈ后,脾淋巴细胞对ＭＴ     

强啡肽和心钠素可能参与可乐定的降压利尿作用

静脉注射可乐定引起大鼠血压降低和心率减慢。此效应可被α受体阻断剂酚妥拉明所对抗。预先腹腔注射大剂量阿片受体阻断剂纳洛酮或静脉注射强啡肽抗体可以部分阻断可乐定的降压效应。静脉注射可乐定可以引起大鼠尿量显著增加,该效应也可被大剂量的纳洛酮所阻断。静脉注射可乐定引起明显的心钠素释放,这一作用可被α受体阻断剂所完全对抗,亦可被阿片受体阻断剂所部分阻断。以上结果说明强啡肽与心钠素可能参与可乐定的降压利尿作用。     

下丘脑减压区微量注射牛磺酸对血压的影响

实验采用微量注射和荧光分光光度测定的方法,探讨了下丘脑前部减压区牛磺酸对大鼠血压的影响及其可能的机制。结果显示：（１）下丘脑前部减压区微量注射牛磺酸可致大鼠血压降低;（２）侧脑室注射β受体阻断剂心得安可阻断牛磺酸的降压效应。而α受体阻断剂酚妥拉明对牛磺酸的降压效应无明显影响;（３）下丘脑前部减压区注射牛磺酸后,可使下丘脑去甲肾上腺素含量明显增高。     

阿托品能阻断α-受体降低大鼠血压

众所周知,阿托品是M—胆碱受体阻断剂,但大剂量阿托品的扩张血管和降压作用却很难用抗胆碱作用来解释。最近S.Abraham等在研究胆碱能神经系统在高血压中的作用时发现,大于阻断M—受体剂量的阿托品可降低大鼠血压。此作用随剂量增大而增强。他们用几种受体阻断剂预先处理动物,然后再观察阿托品的作用,发现预先用心得安(20mg/kg)或六烃季铵(20mg/kg)处理,不能阻断阿托品的降压作用。而用α-受体阻断剂育亨宾(2.5mg/kg)或酚妥拉明(5mg/kg)处理,阿托品的降压作用可完全被阻断。为了进一步弄清阿托品的作用方式,他们还观察了阿托品对几种激动剂引起的血压变化的影响。实验     

家兔第四脑室注射乙酰胆碱对肺动脉血压的影响

本工作将乙酰胆碱(ACh)注入麻醉家兔第四脑室,观察其对肺动脉血压的影响。结果发现(1)脑室注射50—100μg ACh后,肺动脉压和颈动脉压均下降。与此同时心率也出现一过性减慢。(2)切断两侧颈部迷走神经,ACh不再使心率减慢,但其降低肺动脉压和颈动脉压的作用不受到任何影响。(3)预先由第四脑室注射阿托品,可阻断AGh引起的肺动脉降压反应和颈动脉降压反应。(4)第四脑室注射六甲双铵或酚妥拉明,均不能阻断这二个降压反应。(5)第四脑室注射心得安不能阻断ACh引起的肺动脉降压反应,但能阻断ACh降低颈动脉压的作用。 实验结果表明:脑中ACh水平升高可通过激活胆碱能M-受体引起肺动脉压和颈动脉压下降;在ACh引起的颈动脉降压反应的中枢环节中有肾上腺素能β-受体活动参与;而且ACh降低肺动脉压和颈动脉压的作用不是通过迷走神经实现的,可能是由于延髓交感缩血管中枢紧张性降低所造成的。     

侧脑室注射血管紧张素Ⅱ对大鼠血压和缰核内神经元电活动的影响

实验观察了侧脑室注射（ｉｃｖ）及缰核（ｈａｂｅｎｕｌａ ｎｕｃｌｅｕｓ）内微电泳血管紧张素Ⅱ（ＡⅡ）与「Ｓａｒ＾１,Ｔｈｒ＾３」－ＡⅡ（ＳＴ－ＡⅡ,ＡⅡ拮抗剂）对正常和诮激性高血压（ｓｔｒｅｓｓ－ｉｎｄｕｃｅｄ ｈｙｐｅｒｔｅｎｓｉｏｎ ＳＩＨ）大鼠血压及内外侧缰核（ＭＨｂ、ＬＨｂ）内心血管神经元入电活动的影响。结果如下：ｉｃｖ ＡⅡ或ＳＴ－ＡⅡ,正常鼠和ＳＩＨ大鼠血压均升高或降低,ＳＩＨ鼠较正常     

家兔脊髓蛛网膜下腔注射乙酰胆碱对血压和心率的影响

将乙酰胆碱(ACh)注入麻醉家兔脊髓蛛网膜下腔,观察其对心血管活动的影响。结果表明:(1)脊髓蛛网膜下腔注射50～100μg ACh可使血压下降,心率减慢;(2)预先由脊髓蛛网膜下腔注射阿托品,可阻断ACh引起的降压和降心率作用;(3)脊髓蛛网膜下腔注射六甲双铵、酚妥拉明或心得安均不能阻断上述ACh的心血管反应;(4)切断两侧颈部迷走神经,ACh不再使心率减慢,但其降低血压的作用不受到任何影响。 脊髓中ACh水平升高可通过激活胆碱能M-受体引起血压下降和心率减慢。ACh的这种降压作用既没有中枢肾上腺素能受体活动参与,也不是通过迷走神经实现的,可能是由于脊髓交感血管中枢紧张性降低所造成的。     

侧脑室内注射五肽胃泌素对大鼠血压和心率的影响

以动脉血压和心率作为指标,在氨基甲酸乙酯麻醉、三碘季铵酚制动、呼吸机控制呼吸的ＳＤ大鼠上,观察到侧脑室内注射五肽胃泌素（Ｇ５,４μｇ）后动脉血压升高,３ｍｉｎ时达峰值,由给药前的１２．２±１．５ｋＰａ增至１４．６±１．６ｋＰａ;心率增加,其最大值由给药前的４３５±５３．９次／ｍｉｎ,增至４７１．６±５３．２次／ｍｉｎ。而侧脑室注射生理盐水（ｐＨ和容积与Ｇ５相同）或静脉注射同剂量的Ｇ５,对上述指标均无影响。侧脑预先注射α受体阻断剂酚妥拉明（１０μｇ）,可部分桔抗Ｇ５对血压和心率的增加效应;而侧脑室预先注射β受体阻断剂心得安（４μｇ）或侧脑室预先注射Ｍ受体阻断剂阿托品（４μｇ）对Ｇ５的血压和心率增加效应均无影响。结果表明：Ｇ５具有中枢性升高动脉血压和心率的作用,此作用可能部分由脑内α受体介导。     

家兔第四脑室注射P物质对肺动脉压和颈动脉压的影响

本工作将P物质(SP)注入麻醉家兔第四脑室,观察其对肺动脉压和颈动脉压的影响。结果观察到:(1)脑室注射SP后,肺动脉压升高或降低,颈动脉压上升,心率减慢。(2)切断肺动脉压下降组家兔的两侧颈部迷走神经,再ivt.SP,则引起肺动脉压的升高,降心率反应则明显减弱。(3)预先用酚妥拉明或α_1受体阻断剂哌唑嗪均可阻断SP引起的肺动脉和颈动脉升压反应。(4)α_2受体阻断剂育亨宾或纳洛酮均可增强这二个升压反应。(5)心得安对这二个升压反应无明显影响。(6)SP的心血管效应可被SP受体拮抗剂[D-pro~2.D-Trp~(7.9)]-SP阻断。 实验结果表明:脑中SP升高可通过SP受体引起肺动脉压和颈动脉压上升,心率减慢;在SP引起的加压反应的中枢环节中有肾上腺素能α_1受体活动参与;中枢肾上腺素能α_2受体系统和内啡肽系统对传递SP中枢加压作用的路径有抑制性的调制作用。看来,SP与儿茶酚胺及阿片样物质一起参与脑干对血压的调节。     

Cardiovascular effects of histamine administered intracerebroventricularly in critical haemorrhagic hypotension in rats.

The study was designed to determine the cardiovascular effects of histamine administered intracerebroventricularly (icv) in a rat model of volume-controlled haemorrhagic shock. The withdrawal of approximately 50% of total blood volume resulted in the death of all control saline icv treated animals within 30 min. Icv injection of histamine produced a prompt dose-dependent (0.1-100 nmol) and long-lasting (10-100 nmol) increase in mean arterial pressure (MAP), pulse pressure (PP) and heart rate (HR), with a 100% survival of 2h after treatment (100 nmol). The increase in MAP and HR after histamine administration in bled rats in comparison to the normovolaemic animals was 2.7-3.3- and 1.3-3.6-fold higher, respectively. Pretreatment with chlorpheniramine (50 nmol icv), H1 receptor antagonist, inhibited the increase in MAP, PP, HR and survival rate produced by histamine, while chlorpheniramine given alone had no effect. Neither ranitidine (50 nmol icv), H2 histamine receptor antagonist, nor thioperamide (50 nmol icv), H3 receptor blocker, influenced the histamine action, however, when given alone, both evoked the pressor effect with elongation of survival time. It can be concluded that histamine administered icv reverses the haemorrhagic shock conditions, and histamine H1 receptors are involved.     

Further evidence that central neurotensin inhibits pituitary prolactin secretion by stimulating dopamine release from the hypothalamus

Intracerebroventricular (icv) injection of neurotensin (NT) (2 micrograms/rat) suppressed prolactin (PRL) release induced by L-5-hydroxytryptophan (1 mg/100 g body wt, iv), prostaglandin E2(1 microgram/rat, icv), and FK33-824 (10 micrograms/100 g body wt, iv), a Met5-enkephalin analog, in urethane-anesthetized or conscious rats. In contrast, NT did not suppress elevated plasma PRL levels sustained by a large dose of domperidone (10 micrograms/100 g body wt, iv), a peripheral dopamine antagonist. In in vitro experiments, NT (10(-5) M) stimulated dopamine release from perifused rat hypothalamic fragments. These results suggest that central NT inhibits PRL secretion by stimulating dopamine release from the hypothalamus into hypophysical portal blood in the rat.     

Local application of neurotensin to abdominal organs triggers cardiovascular reflexes in guinea pigs: possible mechanisms

Intraabdominal (IAB) injections or topical application of neurotensin (NT) to the serosal surface of the ileum or stomach evoked dose-dependent increases of blood pressure and of heart rate in anesthetized guinea pigs. These effects were markedly reduced by prior animal treatment with a ganglion blocker, alpha and beta adrenoceptor blockers, as well as by exposure of the abdominal organs to lidocaine, a local anesthetic. The blood pressure and heart rate responses to IAB injections or topical application of NT to the ileum or stomach were both inhibited by animal pretreatment with capsaicin. Cervical vagotomy or atropine pretreatment did not prevent or alter the cardiovascular responses to IAB injections of NT. These results suggest the presence in some organs and/or tissues of the abdominal cavity of sympathetic, capsaicin-sensitive sensory nerve fibers which, upon stimulation by NT, produce reflex increases of blood pressure and of heart rate.     

Central Tempol alters basal sympathetic nerve discharge and attenuates sympathetic excitation to central ANG II

In the present study, we established dose-response relationships between central administration of 4-hydroxy-2,2,6,6-tetramethylpiperidine 1-oxyl (Tempol, a superoxide dismutase mimetic) and the level of renal sympathetic nerve discharge (SND) and tested the hypothesis that intracerebroventricular (icv) Tempol pretreatment would attenuate centrally mediated changes in SND produced by icv ANG II administration. Urethane-chloralose-anesthetized, baroreceptor-denervated, normotensive rats were used. We found that icv Tempol administration produced dose-dependent sympathoinhibitory, hypotensive, and bradycardic responses. Mean arterial pressure and SND values were significantly increased after icv ANG II (150 ng/kg) administration, and these responses were abrogated after icv pretreatment with Tempol (75 micromol/kg) or losartan. Brain superoxide levels tended to be higher in ANG II-treated rats compared with rats treated with Tempol and ANG II. Tempol pretreatment did not prevent increases in SND level that were produced by acute heat stress, which indicates specificity in the effect of Tempol in reducing sympathoexcitation. These results demonstrate that icv Tempol administration influences central sympathetic neural circuits in a dose-dependent manner and attenuates SND responses to central ANG II infusion.     

The influence of alpha-fluoromethylhistidine and histamine receptor antagonists on the beta-endorphin-induced corticosterone response

Involvement of a central histaminergic mechanism in the stimulating effect of beta-endorphin (beta-End) on the pituitary-adrenocortical activity, measured indirectly through corticosterone secretion, was investigated in conscious rats. The rise in serum corticosterone levels, induced by beta-End injected intraventricularly (icv) was considerably impaired by pretreatment with naltrexone, an opioid receptor antagonist. The stimulating effect of beta-End was almost totally suppressed by a prior icv administration of mepyramine, a histamine H1-receptor antagonist, and also considerably reduced by pretreatment with cimetidine, an H2-receptor antagonist. The strongest suppression, by 83%; of the beta-End-induced corticosterone response was evoked by a prior administration of alpha-fluoromethylhistidine, an inhibitor of neuronal histamine synthesis in the brain. These results indicate that both the brain neuronal histamine and central histamine H1- and H2-receptors are considerably involved in the beta-endorphin-induced stimulation of the pituitary-adrenocortical activity.     

Central effects of angiotensin II in conscious hamsters: drinking,pressor response,and release of vasopressin

Summary The effects of intracerebroventricular (icv) injections of angiotensin II (ANG II) on water intake, blood pressure, heart rate, and plasma arginine-vasopressin (AVP) concentration were studied in chronically instrumented adult male Syrian golden hamsters (Mesocricetus auratus). Furthermore, the effects of pharmacological ganglionic blockade, and of vascular AVP receptor blockade, on central ANG II-induced cardiovascular responses were investigated. ANG II (1, 10, and 100 ng, icv) elicited dose-dependent increases in water intake and arterial blood pressure. Heart rate showed a biphasic response with a short initial non dose-dependent tachycardic and a subsequent longer lasting bradycardic phase. Plasma AVP concentration was increased two and a half fold with 100 ng ANG II icv. Both ganglionic blockade and vascular AVP receptor blockade significantly attenuated the central ANG II-induced pressor response. The tachycardic phase of the heart rate response was abolished by ganglionic blockade and the bradycardic phase was significantly diminished by AVP receptor blockade. The results support the hypothesis that brain ANG II may participate in the central control of body fluid volume and in central cardiovascular regulation in conscious hamsters.     

Intracerebroventricular injection of hemicholinium-3 lowers blood pressure in conscious spontaneously hypertensive rats but not in normotensive rats

Intracerebroventricular (icv) injection of hemicholinium-3 (HC-3) in doses of 10–20 μg causes a dose-related decrease in the blood pressure of conscious spontaneous hypertensive (SH) rats but not of normotensive rats. HC-3 also reduces heart rate (HR) in both SH and normotensive rats. The bradycardia was blocked by intravenous injection of methylatropine, implicating increased vagal activity as a cause of the response. The decrease in HR also was blocked by icv injection of atropine but not by icv injection of mecamylamine, suggesting that the bradycardia is mediated via central muscarinic receptors. In contrast, the fall in blood pressure in SH rats was not influenced by intravenous administration of methylatropine or by the icv injection of either atropine or mecamylamine.     

Further observations on the mechanism of the cardiovascular reflexes caused by exposure of the peritoneum to neurotensin

Intraperitoneal (IP) injections of either 1, 3 or 9 ml of neurotensin-containing solutions (NTCS) with 5.4, 54, 540 or 5400 nM of neurotensin (NT) were found to cause concentration-dependent, but volume-independent, increases of blood pressure (BP) and heart rate (HR) in anesthetized, close-abdomen guinea pigs. The duration of both effects varied between 15 to 30 min depending both on the NT concentration and volume of NTCS utilized. Indirect evidence suggested that NT inactivation within the peritoneal cavity contributed to shorten the duration of NT effects. Animal pretreatment with a ganglion blocker, adrenoceptor antagonists, clonidine or capsaicin, reduced the BP and HR increases caused by IP injection of NTCS whereas both effects were either unaffected or slightly potentiated by animal pretreatment with atropine, morphine or captopril. Addition of a local anesthetic to NTCS inhibited the hemodynamic effects of NT whereas acute bilateral cervical vagotomy was without significant effect. These results suggest that NT has the ability to trigger cardiovascular reflexes following its IP injection in guinea pigs. The activation of peritoneal, sympathetic, capsaicin-sensitive primary afferents appears to be at the basis of these reflexes, the amplitudes of which seem poorly related to the volume of NTCS utilized (at least within the range of volume examined).     

Central mechanisms of action involved in cocaine-induced tachycardia

The present study was designed to determine the central effects of cocaine on heart rate and blood pressure in Wistar Kyoto rats (WKY) and to evaluate mechanisms involved in the response. Cocaine (0.025-4 mg/kg) was administered to unanesthetized, unrestrained rats via a cannula placed into the lateral ventricle. Procaine (0.1 and 4 mg/kg) was also administered centrally. Cocaine did not significantly alter blood pressure at doses of 0.025, 0.1, or 0.5 mg/kg, icv. Only the highest dose, 4 mg/kg, icv produced a significant pressor response. Cocaine produced significant dose-dependent tachycardia, with the maximum increase in heart rate occurring within 5 min. Procaine (4 mg/kg, icv) produced tachycardia, but the effect was significantly less than that produced by cocaine (4 mg/kg, icv). Cocaine also produced tachycardia at a dose of 0.1 mg/kg, but procaine did not significantly alter heart rate at the same dose. Central phentolamine pretreatment (0.1 mg/kg, icv) significantly attenuated the increase in heart rate produced by cocaine. These results indicate that the centrally mediated tachycardia produced by cocaine is partly due to its local anesthetic activity and to indirect stimulation of alpha receptors.